Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
In this article
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.
GLP-1s are practically everywhere – roughly one in eight U.S. adults take one.
But stopping those drugs may come at a cost.
That’s according to a new study from the Washington University School of Medicine, which was published on Wednesday in BMJ Medicine.
For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their…
In trial, 82% saw weight rebound and cardiovascular health reverse after withdrawal.
GLP-1 agonists could be given to millions with heart conditions to help them stay out of hospital and live longer
Top scientists from have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes.
Women who stop taking GLP-1 medications just prior to a pregnancy appear to be at higher odds for weight gain and complications,…
GLP-1 drugs for weight loss are growing in popularity in the U.S. and across the world. Here's what some users say about their…
